New indolo-β-lactam hybrids as potential anticancer and anti-inflammatory agents

Saeedeh Ghaffari, Aliasghar Jarrahpour, Namik Özdemir, Jean Michel Brunel, Banafsheh Rastegari, Elham Riazimontazer, Edward Turos

DOI: 10.1007/s00044-023-03152-5

Journal: Medicinal Chemistry Research

Molecular docking experiments indicate that the active compounds bind optimally to the 4nos active sites, and suggest that 4e and 9k may serve as potential inhibitors of iNOS for treatment of inflammatory disorders.